MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
3.450
+0.100
+2.99%
After Hours: 3.400 -0.05 -1.45% 19:45 04/08 EDT
OPEN
3.490
PREV CLOSE
3.350
HIGH
3.500
LOW
3.310
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
3.540
52 WEEK LOW
0.9897
MARKET CAP
219.27M
P/E (TTM)
-2.9200
1D
5D
1M
3M
1Y
5Y
1D
MacroGenics Resumes LINNET Trial After FDA Hold Lifted
TipRanks · 10h ago
FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial
Dow Jones · 10h ago
MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study
TipRanks · 11h ago
FDA lifts partial hold on MacroGenics lorigerlimab Phase 2 LINNET trial
Reuters · 11h ago
MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4
Benzinga · 11h ago
MACROGENICS INC - PLAN TO RESUME ENROLLMENT IN CLINICAL STUDY OF LORIGERLIMAB IN GYNECOLOGIC CANCERS
Reuters · 11h ago
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
Barchart · 16h ago
Weekly Report: what happened at MGNX last week (0330-0403)?
Weekly Report · 2d ago
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.